SangStat news

SANG (Menlo Park, Calif.) formed XenoStat Inc., a wholly owned subsidiary, to develop drugs to promote acceptance of animal organs by human recipients, and to develop Ejectine technology to promote the natural rejection of undesirable cells causing disease.

SANG will finance XenoStat via private equity financing and corporate partnering. By placing these long-term technologies in a separate unit, SANG said, it will be able to pursue its goal of becoming profitable in the near term. ...